https://www.prnewswire.com/news-releases/cardiff-oncology-announces-fast-track-designation-granted-by-the-fda-to-onvansertib-for-second-line-treatment-of-kras-mutated-colorectal-cancer-301066789.html
0
0
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
5/28/20 at 12:15pm
Organization
PRNewswire
57 words
0
Comments
SAN DIEGO, May 28, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer,…
You are the first to view
Create an account or login to join the discussion